Skip to main content
. 2021 Oct 17;88(5):2284–2296. doi: 10.1111/bcp.15087

FIGURE 6.

FIGURE 6

Plasma concentration–time profiles for BTK inhibitors. PK profiles were simulated using reported population PK models for acalabrutinib, ACP‐5862 and the total active moiety, 13 ibrutinib 17 and zanubrutinib. 18 Total simulated drug concentrations are shown, not adjusting for differences in protein binding or BTK potency between substrates. BID, twice daily; BTK, Bruton tyrosine kinase; PK, pharmacokinetic; QD, once daily